Our compound screen revealed that vemurafenib resistance led to increased sensitivity to inhibitors of AURK, PLK, tubulin, and kinesin in UACC62 and M238 melanoma cells, whereas M229R cells showed increased sensitivity to 3 different Chk1/2 inhibitors compared with M229P cells (Figure S2 and see Table 1). The gene discussed is PLK1; the disease is melanoma.